We have some exciting news to share! The Motley Fool UK has now become The Twelfth Magpie -- an independent, UK-owned company, led by our long-serving UK management team — Mark Rogers, Chris Nials and Heather Adlington. In practical terms, it’s the same team you know, now fully focused on serving our UK readers and members.

Just as importantly, our approach remains unchanged: long-term, jargon-free, and on your side. This site is our new home, and there will be extra tweaks made across the coming few days as we settle in. So if anything looks a little off, please bear with us!

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

Down 81% since going public, could this iconic FTSE 250 company be a January bargain?

Oliver Rodzianko takes a look at Dr. Martens from the FTSE 250 to see if this could be an opportune time for him to buy some of its shares.

| More on:
Young Caucasian woman with pink her studying from her laptop screen

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Twelfth Magpie’s Premium Investing Services. Become a member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn more, and get a free 'Best Buy Now' stock!.

Investing in shares that are down over 80% can seem daunting. After all, some companies’ share prices fall for good reason. Yet, I think this FTSE 250 business might be an opportunity.

Most people know Dr. Martens (LSE:DOCS) well. It’s become iconic in London, and the brand has spread around the world for its fashionable footwear.

Should you buy Dr. Martens Plc shares today?

Before you decide, please take a moment to review this report first. Despite ongoing uncertainties from US tariffs to global conflicts, Mark Rogers and his team believe many UK shares still trade at substantial discounts, offering savvy investors plenty of potential opportunities to learn about.

That’s why this could be an ideal time to secure this valuable research – Mark’s analysts have scoured the markets to reveal 5 of his favourite long-term ‘Buys’. Please, don’t make any big decisions before seeing them.

The company has had rich cultural significance since the 1960s. It also initiated a successful turnaround culminating in 2010. But are the shares really worth me owning today?

Doc Martens in 2024

This year, the management is focusing on driving sustainable profitability and growth, focusing on shareholder value.

It currently has a strategy called DOCS, focused on direct-to-customer sales, operational excellence, customer connections, and supporting business-to-business partnerships.

The company now operates in three primary regions: Europe, Middle East, and Africa (EMEA); the Americas; and Asia Pacific (APAC).

It sells products from various segments, including Originals, Fusion, Kids, and Casual ranges.

A closer look at the financials

The firm has reported growing revenues and earnings since its initial public offering (IPO) in 2021. However, there’s been significant volatility in the results, particularly for its earnings per share:


Source: TradingView

While the above graph paints a turbulent financial picture for Dr. Martens in the last few years, generally the company’s growth is good.

After all, the firm’s three-year average annual revenue growth rate is over 14%.

Also, the company’s price-to-earnings (P/E) ratio stands at around eight, particularly cheap compared to past prices. It’s also strong for its sector, considering an industry median of around 19.


Source: TradingView

While the above points look relatively promising to me, the organisation’s balance sheet does present some cause for concern.

As of its last annual report in March, it had £446m in debt and only £158m in cash on its books.

While that’s not terrible, it has gotten worse, and taking into account the trailing 12-month period, it has £530m in debt and £46m in cash. If the company faces economic hardships, it might need to raise more finances to pay its debts.

Other risks I’m considering

As of 26 January 2024, the Dr. Marten’s share price had dropped 39% in a year. While the company faced a significant drop in revenue during the period, it did maintain its trading expectations.

To me, that means such a steep decline in the share price was slightly unwarranted. However, it outlines a risk of volatility for Dr. Marten’s shareholders.

Also, while inflation and interest rates are expected to ease soon, there’s no guarantee of this, and any wider economic setbacks could contribute to reduced consumer spending over some time. Therefore, I think the shares might have slower or even negative growth in the near future.

It’s on my watchlist

I’m taking my time before adding these value shares to my portfolio.

As I’ve learned from Warren Buffett: I don’t need to pick many great investments in my lifetime to end up rich. It’s the quality of the ones I choose that really matters. Deciding on that often takes time.

If I do invest, I’ll be giving it at least five years to start seeing the investment returns I’d like. That’s not something I mind, as I like to buy investments with the intention of holding them for at least a decade.

Oliver Rodzianko has no position in any of the shares mentioned. The Motley Fool UK has no position in any of the shares mentioned. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Investing Articles

The latest broker outlooks on Greggs shares look wacky, so what’s happening?

Analyst price targets for Greggs shares are creating some mixed sentiments on where the high-street baker might go next in…

Read more »

Caerphilly Castle, and reflection in the moat.
Investing Articles

2 FTSE 100 dividend stocks that stand out for shareholder returns

Andrew Mackie highlights two FTSE 100 dividend stocks where disciplined capital allocation could continue driving shareholder returns.

Read more »

Senior Adult Black Female Tourist Admiring London
Investing Articles

Just 9% of us can expect a ‘comfortable’ retirement! Could UK shares be the answer?

Millions of Brits could miss out on the retirement of their dreams. Might they avoid this by investing in UK…

Read more »

DIVIDEND YIELD text written on a notebook with chart
Investing Articles

3 passive income shares to consider buying for a 7% yield

Harvey Jones picks out three UK income shares that offer terrific dividends and are trading at tempting valuations. None of…

Read more »

Businessman hand stacking up arrow on wooden block cubes
Investing Articles

How much just £4,160 invested in Rolls-Royce shares 5 years ago is worth now

Rolls-Royce shares have been on a remarkable run of late. Ken Hall takes a look at the key drivers and…

Read more »

Cropped shot of an affectionate young couple posing with a bunch of flowers in their kitchen on their anniversary
Investing Articles

The FTSE 100’s Howden Joinery just made a bold move — should investors care?

Andrew Mackie looks at the FTSE 100’s Howden Joinery and its move into online kitchens, asking what the acquisition means…

Read more »

Queen Street, one of Cardiff's main shopping streets, busy with Saturday shoppers.
Investing Articles

Profits up 173%! Is this surging FTSE small-cap still worth a look?

Ramsdens (LON:RFX) from the FTSE AIM All-Share Index just rose 8%, taking the five-year return above 200%. Why's this under-the-radar…

Read more »

Mature black couple enjoying shopping together in UK high street
Investing Articles

Ramsdens Holdings: a sub-£5 stock offering growth and passive income

This high-flying small-cap stock is paying investors ‘special’ dividends at the moment. Could it be worth considering for passive income?

Read more »